|
1
|
Chen Y, Sun Y, Rao Q, Xu H, Li L and Chang
C: Androgen receptor (AR) suppresses miRNA-145 to promote renal
cell carcinoma (RCC) progression independent of VHL status.
Oncotarget. 6:31203–31215. 2015.PubMed/NCBI
|
|
2
|
King S, Bray S, Galbraith S, Christie L
and Fleming S: Evidence for aldosterone-dependent growth of renal
cell carcinoma. Int J Exp Pathol. 95:244–250. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Min KJ, Jang JH, Lee JT, Choi KS and Kwon
TK: Glucocorticoid receptor antagonist sensitizes TRAIL-induced
apoptosis in renal carcinoma cells through up-regulation of DR5 and
down-regulation of c-FLIP(L) and Bcl-2. J Mol Med (Berl).
90:309–319. 2012. View Article : Google Scholar
|
|
4
|
Poplawski P and Nauman A: Thyroid hormone
- triiodothyronine - has contrary effect on proliferation of human
proximal tubules cell line (HK2) and renal cancer cell lines
(Caki-2, Caki-1) - role of E2F4, E2F5 and p107, p130. Thyroid Res.
1:52008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mellemgaard A, From G, Jørgensen T,
Johansen C, Olsen JH and Perrild H: Cancer risk in individuals with
benign thyroid disorders. Thyroid. 8:751–754. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Prinzi N, Sorrenti S, Baldini E, De Vito
C, Tuccilli C, Catania A, Coccaro C, Bianchini M, Nesca A, Grani G,
et al: Association of thyroid diseases with primary extra-thyroidal
malignancies in women: Results of a cross-sectional study of 6,386
patients. PLoS One. 10:e01229582015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Videla LA, Fernández V, Cornejo P, Vargas
R and Castillo I: Thyroid hormone in the frontier of cell
protection, survival and functional recovery. Expert Rev Mol Med.
17:e102015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shin DH, Lee MJ, Lee HS, Oh HJ, Ko KI, Kim
CH, Doh FM, Koo HM, Kim HR, Han JH, et al: Thyroid hormone
replacement therapy attenuates the decline of renal function in
chronic kidney disease patients with subclinical hypothyroidism.
Thyroid. 23:654–661. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Katz AI, Emmanouel DS and Lindheimer MD:
Thyroid hormone and the kidney. Nephron. 15:223–249. 1975.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Puzianowska-Kuznicka M, Pietrzak M,
Turowska O and Nauman A: Thyroid hormones and their receptors in
the regulation of cell proliferation. Acta Biochim Pol. 53:641–650.
2006.PubMed/NCBI
|
|
11
|
Basu G and Mohapatra A: Interactions
between thyroid disorders and kidney disease. Indian J Endocrinol
Metab. 16:204–213. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Humes HD, Cieslinski DA, Johnson LB and
Sanchez IO: Triiodothyronine enhances renal tubule cell replication
by stimulating EGF receptor gene expression. Am J Physiol.
262:F540–F545. 1992.PubMed/NCBI
|
|
13
|
Samad MA, Haque MM, Shah MK, Islam MR and
Mia MC: Evaluation of TSH, T4 and T3 in human serum:
Standardization on normal individuals American. J Mod Phys.
2:202–207. 2013.
|
|
14
|
Samuels HH and Tsai JS: Thyroid hormone
action in cell culture: Domonstration of nuclear receptors in
intact cells and isolated nuclei. Proc Natl Acad Sci USA.
70:3488–3492. 1973. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Maia AL, Goemann IM, Meyer EL and Wajner
SM: Deiodinases: the balance of thyroid hormone: type 1
iodothyronine deiodinase in human physiology and disease. J
Endocrinol. 209:283–297. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Niemczyk S, Dudek M, Bartoszewicz Z,
Szamotulska K, Woźniacki L, Brodowska-Kania D, Niemczyk L, Małek W
and Matuszkiewicz-Rowińska J: Determining the enzymatic activities
of iodothyronine 5′-deiodinases in renal medulla and cortex.
Endokrynol Pol. 64:182–185. 2013.
|
|
17
|
Pachucki J, Ambroziak M, Tanski Z, Luczak
J, Nauman J and Nauman A: Type I 5′-iodothyronine deiodinase
activity and mRNA are remarkably reduced in renal clear cell
carcinoma. J Endocrinol Invest. 24:253–261. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rini BI, Tamaskar I, Shaheen P, Salas R,
Garcia J, Wood L, Reddy S, Dreicer R and Bukowski RM:
Hypothyroidism in patients with metastatic renal cell carcinoma
treated with sunitinib. J Natl Cancer Inst. 99:81–83. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tamaskar I, Bukowski R, Elson P,
Ioachimescu AG, Wood L, Dreicer R, Mekhail T, Garcia J and Rini BI:
Thyroid function test abnormalities in patients with metastatic
renal cell carcinoma treated with sorafenib. Ann Oncol. 19:265–268.
2008. View Article : Google Scholar
|
|
20
|
Schmidinger M, Vogl UM, Bojic M, Lamm W,
Heinzl H, Haitel A, Clodi M, Kramer G and Zielinski CC:
Hypothyroidism in patients with renal cell carcinoma: Blessing or
curse? Cancer. 117:534–544. 2011. View Article : Google Scholar
|
|
21
|
Mousa SA, Lin HY, Tang HY, Hercbergs A,
Luidens MK and Davis PJ: Modulation of angiogenesis by thyroid
hormone and hormone analogues: Implications for cancer management.
Angiogenesis. 17:463–469. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu X, Zheng N, Shi YN, Yuan J and Li L:
Thyroid hormone induced angiogenesis through the integrin
αvβ3/protein kinase D/histone deacetylase 5
signaling pathway. J Mol Endocrinol. 52:245–254. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Davis PJ, Davis FB and Mousa SA: Thyroid
hormone-induced angiogenesis. Curr Cardiol Rev. 5:12–16. 2009.
View Article : Google Scholar
|
|
24
|
Borek C, Guernsey DL, Ong A and Edelman
IS: Critical role played by thyroid hormone in induction of
neoplastic transformation by chemical carcinogens in tissue
culture. Proc Natl Acad Sci USA. 80:5749–5752. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Guernsey DL, Borek C and Edelman IS:
Crucial role of thyroid hormone in x-ray-induced neoplastic
transformation in cell culture. Proc Natl Acad Sci USA.
78:5708–5711. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Moeller LC and Führer D: Thyroid hormone,
thyroid hormone receptors, and cancer: A clinical perspective.
Endocr Relat Cancer. 20:R19–R29. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim WG and Cheng SY: Thyroid hormone
receptors and cancer. Biochim Biophys Acta. 1830:3928–3936. 2013.
View Article : Google Scholar
|
|
28
|
Yalcin M, Bharali DJ, Lansing L, Dyskin E,
Mousa SS, Hercbergs A, Davis FB, Davis PJ and Mousa SA:
Tetraidothyroacetic acid (tetrac) and tetrac nanoparticles inhibit
growth of human renal cell carcinoma xenografts. Anticancer Res.
29:3825–3831. 2009.PubMed/NCBI
|
|
29
|
van der Hout AH, van der Vlies P, Wijmenga
C, Li FP, Oosterhuis JW and Buys CH: The region of common allelic
losses in sporadic renal cell carcinoma is bordered by the loci
D3S2 and THRB. Genomics. 11:537–542. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yokota J, Mori N, Akiyama T, Shimosato Y,
Sugimura T and Terada M: Multiple genetic alterations in small-cell
lung carcinoma. Princess Takamatsu Symp. 20:43–48. 1989.PubMed/NCBI
|
|
31
|
Hu CY, Mohtat D, Yu Y, Ko YA, Shenoy N,
Bhattacharya S, Izquierdo MC, Park AS, Giricz O, Vallumsetla N, et
al: Kidney cancer is characterized by aberrant methylation of
tissue-specific enhancers that are prognostic for overall survival.
Clin Cancer Res. 20:4349–4360. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Network TCGAR; Cancer Genome Atlas
Research Network. Comprehensive molecular characterization of clear
cell renal cell carcinoma. Nature. 499:43–49. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kamiya Y, Puzianowska-Kuznicka M, McPhie
P, Nauman J, Cheng SY and Nauman A: Expression of mutant thyroid
hormone nuclear receptors is associated with human renal clear cell
carcinoma. Carcinogenesis. 23:25–33. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rosen MD and Privalsky ML: Thyroid hormone
receptor mutations in cancer and resistance to thyroid hormone:
Perspective and prognosis. J Thyroid Res. 2011:3613042011.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rosen MD and Privalsky ML: Thyroid hormone
receptor mutations found in renal clear cell carcinomas alter
corepressor release and reveal helix 12 as key determinant of
corepressor specificity. Mol Endocrinol. 23:1183–1192. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Turowska O, Nauman A, Pietrzak M,
Popławski P, Master A, Nygard M, Bondesson M, Tanski Z and
Puzianowska-Kuznicka M: Overexpression of E2F1 in clear cell renal
cell carcinoma: A potential impact of erroneous regulation by
thyroid hormone nuclear receptors. Thyroid. 17:1039–1048. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nauman A, Turowska O, Poplawski P, Master
A, Tanski Z and Puzianowska-Kuznicka M: Elevated cyclin E level in
human clear cell renal cell carcinoma: Possible causes and
consequences. Acta Biochim Pol. 54:595–602. 2007.PubMed/NCBI
|
|
38
|
Rosen MD, Chan IH and Privalsky ML: Mutant
thyroid hormone receptors (TRs) isolated from distinct cancer types
display distinct target gene specificities: A unique regulatory
repertoire associated with two renal clear cell carcinomas. Mol
Endocrinol. 25:1311–1325. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wojcicka A, Piekielko-Witkowska A,
Kedzierska H, Rybicka B, Poplawski P, Boguslawska J, Master A and
Nauman A: Epigenetic regulation of thyroid hormone receptor beta in
renal cancer. PLoS One. 9:e976242014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Puzianowska-Kuznicka M, Nauman A, Madej A,
Tanski Z, Cheng S and Nauman J: Expression of thyroid hormone
receptors is disturbed in human renal clear cell carcinoma. Cancer
Lett. 155:145–152. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Master A, Wójcicka A, Piekiełko-Witkowska
A, Bogusławska J, Popławski P, Tański Z, Darras VM, Williams GR and
Nauman A: Untranslated regions of thyroid hormone receptor beta 1
mRNA are impaired in human clear cell renal cell carcinoma. Biochim
Biophys Acta. 1802:995–1005. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ebert T, Bander NH, Finstad CL, Ramsawak
RD and Old LJ: Establishment and characterization of human renal
cancer and normal kidney cell lines. Cancer Res. 50:5531–5536.
1990.PubMed/NCBI
|
|
43
|
Tanaka T, Torigoe T, Hirohashi Y, Sato E,
Honma I, Kitamura H, Masumori N, Tsukamoto T and Sato N:
Hypoxia-inducible factor (HIF)-independent expression mechanism and
novel function of HIF prolyl hydroxylase-3 in renal cell carcinoma.
J Cancer Res Clin Oncol. 140:503–513. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gati A, Da Rocha S, Guerra N, Escudier B,
Moretta A, Chouaib S, Angevin E and Caignard A: Analysis of the
natural killer mediated immune response in metastatic renal cell
carcinoma patients. Int J Cancer. 109:393–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Beck-Peccoz P, Chatterjee VK, Chin WW,
DeGroot LJ, Jameson JL, Nakamura H, Refetoff S, Usala SJ and
Weintraub BD: Nomenclature of thyroid hormone receptor beta-gene
mutations in resistance to thyroid hormone: Consensus statement
from the first workshop on thyroid hormone resistance, July 10–11,
1993, Cambridge, United Kingdom. J Clin Endocrinol Metab.
78:990–993. 1994.PubMed/NCBI
|
|
46
|
Sakurai A, Nakai A and DeGroot LJ:
Structural analysis of human thyroid hormone receptor beta gene.
Mol Cell Endocrinol. 71:83–91. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Curran PJ, Obeidat K and Losardo D: Twelve
frequently asked questions about growth curve modeling. J Cogn Dev.
11:121–136. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yuan JS, Reed A, Chen F and Stewart CN Jr:
Statistical analysis of real-time PCR data. BMC Bioinformatics.
7:852006. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hoch FL: Biochemistry of hyperthyroidism
and hypothyroidism. Postgrad Med J. 44:347–362. 1968. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ohba K, Takayama T, Matsunaga H,
Matsushita A, Sasaki S, Oki Y, Ozono S and Nakamura H:
Inappropriate elevation of serum thyrotropin levels in patients
treated with axitinib. Thyroid. 23:443–448. 2013. View Article : Google Scholar
|
|
51
|
Bozkurt O, Karaca H, Hacibekiroglu I, et
al: Is sunitinib-induced hypothyroidism a predictive clinical
marker for better response in metastatic renal cell carcinoma
patients? J Chemother. 1973947815Y0000000039. 2015.PubMed/NCBI
|
|
52
|
Riesenbeck LM, Bierer S, Hoffmeister I,
Köpke T, Papavassilis P, Hertle L, Thielen B and Herrmann E:
Hypothyroidism correlates with a better prognosis in metastatic
renal cancer patients treated with sorafenib or sunitinib. World J
Urol. 29:807–813. 2011. View Article : Google Scholar
|
|
53
|
Nearchou A, Valachis A, Lind P, Akre O and
Sandström P: Acquired hypothyroidism as a predictive marker of
outcome in patients with metastatic renal cell carcinoma treated
with tyrosine kinase inhibitors: A literature-based meta-analysis.
Clin Genitourin Cancer. 13:280–286. 2015. View Article : Google Scholar
|
|
54
|
Krenning EP, Docter R, Visser TJ and
Hennemann G: The significance of plasma membrane transport of
iodothyronines in the regulation of thyroid hormone
bioavailability. Acta Med Austriaca. 15(Suppl 1): 15–17.
1988.PubMed/NCBI
|
|
55
|
Samuels HH, Tsai JS and Cintron R: Thyroid
hormone action: A cell-culture system responsive to physiological
concentrations of thyroid hormones. Science. 181:1253–1256. 1973.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Yen PM: Physiological and molecular basis
of thyroid hormone action. Physiol Rev. 81:1097–1142.
2001.PubMed/NCBI
|
|
57
|
Cunha Lima ST and Rodrigues ED: The
oligomeric state of thyroid receptor regulates hormone binding
kinetics. J Endocrinol. 210:125–134. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Capasso G, De Santo NG and Kinne R:
Thyroid hormones and renal transport: Cellular and biochemical
aspects. Kidney Int. 32:443–451. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Trachtman H, Jacques C, Citron J and
Futterweit S: Effect of triiodothyronine on nitric oxide production
in mesangial cells and renal tubular epithelial cells. Res Commun
Mol Pathol Pharmacol. 93:69–78. 1996.PubMed/NCBI
|
|
60
|
Ward HH, Romero E, Welford A, Pickett G,
Bacallao R, Gattone VH II, Ness SA, Wandinger-Ness A and Roitbak T:
Adult human CD133/1(+) kidney cells isolated from papilla integrate
into developing kidney tubules. Biochim Biophys Acta.
1812:1344–1357. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Choi JW and Choi HS: The regulatory
effects of thyroid hormone on the activity of
3-hydroxy-3-methylglutaryl coenzyme A reductase. Endocr Res.
26:1–21. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Moeller LC, Wardrip C, Niekrasz M,
Refetoff S and Weiss RE: Comparison of thyroidectomized calf serum
and stripped serum for the study of thyroid hormone action in human
skin fibroblasts in vitro. Thyroid. 19:639–644. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Alini M, Kofsky Y, Wu W, Pidoux I and
Poole AR: In serum-free culture thyroid hormones can induce full
expression of chondrocyte hypertrophy leading to matrix
calcification. J Bone Miner Res. 11:105–113. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
de Oliveira M, Luvizotto RA, Olimpio RM,
De Sibio MT, Conde SJ, Biz Rodrigues Silva C, Moretto FC and
Nogueira CR: Triiodothyronine increases mRNA and protein leptin
levels in short time in 3T3-L1 adipocytes by PI3K pathway
activation. PLoS One. 8:e748562013. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Reynolds AM, Surks MI and Shapiro LE: The
effects of chronic exposure to supraphysiological concentrations of
3, 5, 3′ triiodo-L-thyronine (T3) on cultured GC cells. J Cell
Physiol. 149:544–547. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Ryan MJ, Johnson G, Kirk J, Fuerstenberg
SM, Zager RA and Torok-Storb B: HK-2: An immortalized proximal
tubule epithelial cell line from normal adult human kidney. Kidney
Int. 45:48–57. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Wang WM, Chung MH and Huang SM: Regulation
of nuclear receptor activities by two human papillomavirus type 18
oncoproteins, E6 and E7. Biochem Biophys Res Commun. 303:932–939.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Wu MH, Huang CJ, Liu ST, Liu PY, Ho CL and
Huang SM: Physical and functional interactions of human
papillomavirus E2 protein with nuclear receptor coactivators.
Biochem Biophys Res Commun. 356:523–528. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Bens M and Vandewalle A: Cell models for
studying renal physiology. Pflugers Arch. 457:1–15. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Simonides WS, Mulcahey MA, Redout EM,
Muller A, Zuidwijk MJ, Visser TJ, Wassen FW, Crescenzi A, da-Silva
WS, Harney J, et al: Hypoxia-inducible factor induces local thyroid
hormone inactivation during hypoxic-ischemic disease in rats. J
Clin Invest. 118:975–983. 2008.PubMed/NCBI
|
|
71
|
Foster DA, Yellen P, Xu L and Saqcena M:
Regulation of G1 cell cycle progression: Distinguishing the
restriction point from a nutrient-sensing cell growth
checkpoint(s). Genes Cancer. 1:1124–1131. 2010. View Article : Google Scholar
|
|
72
|
Cooper S: On the interpretation of the
shortening of the G1-phase by overexpression of cyclins in
mammalian cells. Exp Cell Res. 238:110–115. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Pernitsky AN and Anderson JE: Differential
effects of 3,5,3′-triio-dothyronine on control and mdx myoblasts
and fibroblasts: Analysis by flow cytometry. Exp Cell Res.
227:214–222. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Maruvada P, Dmitrieva NI, East-Palmer J
and Yen PM: Cell cycle-dependent expression of thyroid hormone
receptor-beta is a mechanism for variable hormone sensitivity. Mol
Biol Cell. 15:1895–1903. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Lin YC, Boone M, Meuris L, Lemmens I, Van
Roy N, Soete A, Reumers J, Moisse M, Plaisance S, Drmanac R, et al:
Genome dynamics of the human embryonic kidney 293 lineage in
response to cell biology manipulations. Nat Commun. 5:47672014.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Jansson M, Philipson L and Vennström B:
Isolation and characterization of multiple human genes homologous
to the oncogenes of avian erythroblastosis virus. EMBO J.
2:561–565. 1983.PubMed/NCBI
|
|
77
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBio-Portal. Sci Signal. 6:pl12013. View Article : Google Scholar
|
|
79
|
Mermel CH, Schumacher SE, Hill B, Meyerson
ML, Beroukhim R and Getz G: GISTIC2.0 facilitates sensitive and
confident localization of the targets of focal somatic copy-number
alteration in human cancers. Genome Biol. 12:R412011. View Article : Google Scholar : PubMed/NCBI
|
